Singularity Biomed Joins the AutoPiX Consortium Funded by Horizon Europe

We are pleased to announce that Singularity Biomed is part of the AutoPiX consortium, an ambitious international project funded by the Innovative Health Initiative (IHI) of the European Commission, under the Horizon Europe framework.

What is AutoPiX?

AutoPiX is an international project focused on improving healthcare for people with rheumatic and musculoskeletal diseases (RMDs). The project brings together pharmaceutical and medical technology partners with leading academic institutions to enhance the use of imaging biomarkers in patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis.

Its goal is to develop advanced imaging tools and artificial intelligence (AI) models to better diagnose, monitor, and treat these conditions.

Funding: Horizon Europe and IHI

This project is made possible by the support of Horizon Europe and the IHI.

Horizon Europe

Horizon Europe is the European Union's key funding programme for research and innovation (R&I) for the 2021-2027 period. It is the EU's main instrument to foster scientific and technological competitiveness, addressing major global challenges such as health and climate change.

Innovative Health Initiative (IHI)

The Innovative Health Initiative (IHI) is an institutionalized public-private partnership under Horizon Europe. Its mission is to translate health research and innovation into tangible benefits for patients and society, ensuring that Europe remains at the forefront of interdisciplinary, sustainable, and patient-centric health research.

Singularity Biomed's Role

At Singularity Biomed, our role in this project is to participate in prospective clinical studies. This will allow us to not only validate our Artificial Intelligence models for assessing arthritis using thermal imaging, but also potentially improve them with new data.

This validation will be carried out in an international patient cohort that includes centers in Germany, Denmark, Switzerland, and Austria.

The results of these studies will allow us to advance significantly towards the necessary regulatory phases and the subsequent market launch of our technology, bringing us closer to our mission of improving the quality of life for patients with arthritis.

For more information about the project, visit https://www.autopix-project.eu.